Latest Breaking News On - Federated hermes kaufmann funds - Page 4 : comparemela.com

Regulus Therapeutics Reports First Quarter 2023 Financial Results and Recent Updates

/PRNewswire/ Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines.

United statesSan diegoCris calsadaSarah suttonJay haganRegulus therapeutics incProgram updatesRnas the company or regulusEnterprise associatesDevelopment rd expensesExchange commissionAutosomal dominant polycystic kidney diseaseMultiple ascending dosePrivate placementFederated hermes kaufmann fundsNew enterprise associates

Regulus Therapeutics (RGLS) Announces $15M Private Placement

Regulus Therapeutics (RGLS) Announces $15M Private Placement
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesHc wainwright coRegulus therapeutics incEnterprise associatesRnas the company or regulusFederated hermes kaufmann fundsNew enterprise associatesCommon stockSecurities act

Regulus Therapeutics Announces $15 Million Private Placement of Equity

Regulus Therapeutics Announces $15 Million Private Placement of Equity
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSan diegoExchange commissionRnas the company or regulusPrnewswire regulus therapeutics incRegulus therapeutics incEnterprise associatesHc wainwright coFederated hermes kaufmann fundsNew enterprise associatesCommon stockSecurities actPrivate securities litigation reform act

Fusion Pharmaceuticals Announces Fourth Quarter 2022 Financial Results and Clinical Program Updates

/PRNewswire/ Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as.

United statesJohn valliantAmanda crayFusion pharmaceuticals incWoodline master fundNiowave incDeerfield management companyAmerican association for cancer researchPrnewswire fusion pharmaceuticals incFusion pharmaceuticalsInvestor relations corporate communicationsExecutive officer john valliantAvidity partnersFederated hermes kaufmann fundsPerceptive advisorsAmerican association

Fusion Pharmaceuticals to Acquire Phase 2 Program for 225Ac-PSMA I&T, a Radiopharmaceutical Targeting Metastatic Castrate Resistant Prostate Cancer

/PRNewswire/ Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) ("Fusion"), a clinical-stage oncology company focused on developing next-generation targeted alpha.

United statesEbrahim delpassandJohn valliantAmanda crayFusion pharmaceuticals incMorgan stanleySpica centerDeerfield management companyLaborde professor for cancer researchPrnewswire fusion pharmaceuticals incRadiomedix incFusion pharmaceuticalsWoodline master fundNiowave incTulane cancer centerExchange commission